Contact Us | Print Page | Sign In | Register
News & Press: Industry News for MS (INforMS)

CMSC INforMS: Multiple Sclerosis Therapy Can 'Reverse Disease'

Friday, June 10, 2016  
Posted by: Elizabeth Porco
Share |

The high-risk treatment reversed the symptoms of some patients in a trial, but the therapy is not suitable for all MS sufferers.

A radical treatment can halt the progression of multiple sclerosis and even reverse symptoms of the autoimmune disease, research suggests.

The "highly exciting" therapy involves destroying the patient's immune system and regenerating a new one using stem cells taken from their bone marrow.

A 13-year trial involving 24 people with a highly active, relapsing form of MS saw 70% of patients experience a complete halt in the disease's progression.

In 40% of patients, symptoms such as vision loss, balance problems and muscle weakness were reversed for prolonged periods of time.

Although doctors say the findings hold a lot of promise, experts have warned the treatment can have serious side effects and risks.

It is also thought the therapy will only help a small proportion of patients in the early stages of MS - and patients who have had significant disabilities for a prolonged period of time are unlikely to benefit.

One of the main dangers associated with the therapy is the threat of infection for patients while they are unprotected by an immune system.

The treatment is known as IAHSCT (immunoablation and autologous hematopoietic stem cell transplantation) and a similar procedure has been used for treating patients with life-threatening leukaemia for several decades.

Jennifer Molson, who participated in the MS trial six years after she was diagnosed with the disease, said: "Before my transplant, I was unable to talk or work and was living in assisted care. Now, I am able to walk independently, live in my own home and work full time.

"I was also able to get married, walk down the aisle with my dad and dance with my husband. I've even gone downhill skiing."

The MS Society in the UK has welcomed the findings, published in the Lancet journal, as it "provided valuable information about the long-term safety and effectiveness" of the treatment.

Professor Siddharthan Chandran, from the Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh, said the study appeared to render some of the patients in the study "effectively disease-free".

He added: "However, the treatment regime has substantial risks and safety concerns that underline the need for future studies with a larger sample size, control group and ideally identification of predictive markers to allow targeting of this treatment to those MS patients at greatest risk of rapid and severe decline."

Sky News

CMSC Disclaimer 
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275